Imaging Diagnostic Systems Achieves Technical Breakthrough with New Reconstruction Algorithm

FORT LAUDERDALE, Fla.--(Business Wire)--
Imaging Diagnostic Systems, Inc., (OTCBB:IMDS)a pioneer in laser optical breast
cancer imaging systems, announced today that it has enhanced its CT Laser
Mammography (CTLM) system with a reconstruction algorithm that improves
visualization of angiogenesis (cancer) in its images.

During a CTLM examination the breast is illuminated by a laser and the
transmitted light is collected by a series of photo detectors and transformed
into digital data. The reconstruction algorithm uses this data to create the
various images of the breasts. The improved algorithm enhances the images by
reducing the number of artifacts occasionally produced during an examination
thereby making diagnosis easier.

"Our first-generation reconstruction algorithms were developed and evaluated
using data acquired during our initial clinical trials. Since those trails, we
have deployed over 26 systems worldwide, providing us with CTLM data from
thousands of patients. IDSI`s Research & Development team used this data to
optimize the reconstruction algorithms in order to provide better clarity and
reduced artifact in CTLM images. We also incorporated streamlined numerical
methods into the software so that the new algorithm does not require additional
computing resources, allowing us to provide the improved functionality to
existing customers as a software upgrade," stated Steven Ponder, Ph.D., Director
of Advanced Development/Imaging Diagnostic Systems.

"The new algorithm has improved the visualization and distinction of several
known patterns of angiogenesis from normal patterns of breast perfusion, making
it easier for the radiologist to detect cancer. Of even greater importance;
breasts which are too dense to be penetrated by X-ray mammography are quite
translucent to the laser beam. The CTLM system therefore has much greater
sensitivity than mammography in the dense breast and can reveal between two and
three times the number," stated Dr. Eric Milne Director of Clinical
Research/Imaging Diagnostic Systems Inc.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging
device to aid in the detection and management of breast cancer. The CTLM system
is a patented new breast imaging system that utilizes continuous wave laser
technology and patented algorithms to create 3-D images of the breast. The
procedure is non-invasive, painless, and does not expose the patient to ionizing
radiation or painful breast compression. CT Laser Mammography (CTLM®) is
designed to be used in conjunction with mammography. It reveals information
about blood distribution in the breast and may visualize the process of
angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for
the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography
Laser Mammography (CTLM) system to be used as an adjunct to mammography. The FDA
has determined that the Company`s clinical study is a non-significant risk (NSR)
investigational device study under 812.3(m) of the investigational device
exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United
States Federal Law to investigational use only in the United States. The CTLM
system has received other registrations including CE, CMDCAS Canadian License,
China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our corporate website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private
Securities Litigation Reform Act of 1995, this news release may contain
forward-looking statements pertaining to future, anticipated, or projected
plans, performances and developments, as well as other statements relating to
future operations. All such forward-looking statements are necessarily only
estimates or predictions of future results or events and there can be no
assurance that actual results or events will not materially differ from
expectations. Further information on potential factors that could affect Imaging
Diagnostic Systems, Inc., is included in the Company`s filings with the
Securities and Exchange Commission. We expressly disclaim any intent or
obligation to update any forward-looking statements.

Imaging Diagnostic Systems, Inc., Fort Lauderdale
Deborah O'Brien, 954-581-9800

Copyright Business Wire 2009